LTP

LTR PHARMA FPO [LTP]
LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.
Healthcare · ASX Small Cap
$0.4900 -3.0%

Updated 22 Jul 2026 · Signals refresh every scan

Get alerts when LTP triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track LTP — Free

Active Signals

Bullish Signals

  • Above-average volume (1.5x) on a red day — sellers in control
  • Smart money may be accumulating — volume is flowing in even though price hasn't moved yet
  • Lagging the Small Ords index — relative strength of 0.86, underperforming its peers
  • Strong cash runway (15 quarters)
  • Very high P/S ratio (79.5x)
  • Revenue in sharp decline (-84%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (6.08%/day)
  • Altman Z-Score grey zone (1.90, low-confidence approx)
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 7d (+5pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -84% — the top line is shrinking
Ask Scout AI about LTP
"What's driving LTP today?" "How does LTP compare to peers?" "Key risks for LTP?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE LTR Executes U.S. Commercial Agreement with Strive
NONE LTR Executes Definitive U.S. Commercial Agreement with Shed
NONE Notification regarding unquoted securities - LTP
Announcement tone +5pts

Recent ASX Announcements

2026-07-19 LTR Executes U.S. Commercial Agreement with Strive PRICE SENSITIVE
2026-07-16 LTR Executes Definitive U.S. Commercial Agreement with Shed PRICE SENSITIVE
2026-07-10 Notification regarding unquoted securities - LTP
2026-06-23 OROFLOW Clinical Study Receives Ethics Approval
2026-06-15 Response to ASX Aware Letter PRICE SENSITIVE

Key Metrics

$90.0M
Market Cap
297K
Avg Volume
1.5x
Vol Ratio
$0.31 — $0.81
52-Week Range
0.1%
Short Interest
N/A
Cash Runway
-29.3%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 59%
LLeader vs LaggardpassRS: 10
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:LTP vs IDTLTP vs ADRLTP vs LDX
Scout Pro — Deeper Analysis for LTP
Try Pro free for 30 days
Share this analysis

Track LTP and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required